A Trial of Fimasartan for Early Diastolic Heart Failure
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Approximately half of hypertensive patients have diastolic dysfunction and diastolic
dysfunction is associated with development of congestive heart failure and increased
mortality. Although diastolic heart failure associated with hypertension is a clinically
significant problem, few clinical trials have been conducted and there is no proven
pharmacological therapy to improve outcomes. To the best of the investigators knowledge,
there has been no randomized trial to demonstrate that an antihypertensive drug improves
diastolic function in hypertensive patients with diastolic dysfunction. The investigators
hypothesize that fimasartan added to standard therapy will be superior to placebo in
improving diastolic dysfunction in mildly symptomatic patients with hypertension and
diastolic dysfunction, and try to examine this hypothesis in a double-blind, randomized
comparison study using echocardiography.